Home > OJMM>
Biography

Dr. Zdenek Hel
Dept. of Pathology, Division of Molecular and Cellular Pathology
University of Alabama at Birmingham,
USA

Email: zhel@uab.edu

Qualifications
1997   Ph.D., McGill University, Canada
1990   M.Sc., Charles University, Czech Republic

Publications

  1. Denning, W., Xu, J., Guo, S., Klug, C., and Z. Hel. 2011. Limited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responses. PLoS ONE 6:e16897.
  2. Hel, Z., Stringer, E., and J. Mestecky. 2010. Sex steroid hormones, hormonal contraception and the immunobiology of HIV-1 infection. Endocr. Rev. 31:79-97.
  3. Xu,J., Kelly, M., Denning, W., and Z. Hel. 2009. A model for testing the immunogenicity of SIV and SHIV vaccine candidates in mice. J. Virol. Meth. 158: 70.
  4. Guo, S., Xu, J., Denning, W., and Z. Hel. 2009. Induction of protective cytotoxic T cell responses by a B cell-based cellular vaccine requires stable expression of antigen. Gene Ther. 16:1600-1613.
  5. Mestecky, J., Moldoveanu, Z., Smith, P.D., Hel, Z., and R.C. Alexander. 2009. Mucosal immunology of the genital tract and HIV infection. J Reprod. Immunol. 83:186-200.
  6. Raska, M., Moldoveanu, Z., Novak, J., Hel, Z., Bozja, J., Compans, R.W., Yang, C., and J. Mestecky. 2008. Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. Vaccine. 26: 1541-1551.
  7. Hel, Z., Tsai, W.-P., Tryniszewska, E., Nacsa, J., Markham, P.D., Lewis, M.G., Pavlakis, G.N., Felber, B.K., Tartaglia, J., and Franchini, G. 2006. Improved vaccine protection from simian AIDS by the addition of nonstructural SIV genes. J. Immunol. 176:85-96.
  8. Pal, R., Venzon, D., Santra, S., Kalyanaraman, V.S., Montefiori, D.C., Hocker, L., Hudacik, L., Rose, N., Nacsa, J., Edghill-Smith, Y., Moniuszko, M., Hel, Z., Belyakov, I.M.,Berzofsky, J.A., Washington-Parks, R., Markham, P.D., Letvin, N.L., Tartaglia, J., and G. Franchini. 2006. Systemic immunization with an ALVAC-HIV-1 / protein boost vaccine strategy protects rhesus macaques from CD4+ T cell loss and reduces both systemic and mucosal SHIVKU2 RNA levels. J. Virol. 80:3732.
  9. Hel, Z., McGhee, J., Mestecky, J. 2006. HIV infection: First battle decides the war. Trends Immunol. 27: 274-281.
  10. Garnon, J., Lachance, C., Di Marco, S., Hel, Z., Marion, D., Ruiz, M.C., Newkirk, M.M., Khandjian, E.W., and D. Radzioch. 2005. Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the posttranscriptional level. J. Biol. Chem. 280:5750-63.
  11. Pal, R., Venzon, D., Letvin, N.L., Santra, S., Montefiori, D.C., Miller, N.R., Tryniszewska, E., Lewis, M.G., VanCott, T.C., Hirsch, V., Woodward, R., Gibson, A., Grace, M., Dobratz, E., Markham, P.D., Hel, Z., Nacsa, J., Klein, M., Tartaglia, J., and G. Franchini. 2002. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay Simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76: 292-302.
  12. Stevceva, L., Kelsall, B., Nacsa, J., Moniuszko, M., Hel, Z., Tryniszewska, E., and G. Franchini. 2002. Cervicovaginal lamina propria lymphocytes: Phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to Simian immunodeficiency virus SIV(mac251). J. Virol. 76: 9-18.
  13. Hel, Z., Johnson, J.M., Tryniszewska, E., Tsai, W.P., Harrod, R., Fullen, J., Tartaglia, J., and G. Franchini. 2002. A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine 20:3171-3186.
  14. Hel, Z. Nacsa,J., Tryniszewska, E., Tsai, W.P., Washington-Parks, R., Montefiori, D.C., Felber, B.K., Pavlakis, G.N., Tartaglia,J., and G. Franchini. 2002. Containment of SIV infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and post-challenge CD4+ and CD8+ T-cell responses. J. Immunol. 169:4778-4787.
  15. Hel, Z., Nacsa, J., Tsai, W.P., Thornton, A., Giuliani, L., Tartaglia, J., and G. Franchini. 2002. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304:125-134.
  16. Tryniszewska, E., Nacsa, J., Lewis, M.G., Silvera, P., Venzon, D., Hel, Z., Washington Parks, R., Maniuszko, M., Tartaglia, J., Smith, K.A., and G. Franchini. 2002. Vaccination of macaques with long standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immunol. 169:5347-5357.